Hong Zhi, Cameron Craig E
Drug Discovery, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa, CA 92626, USA.
Prog Drug Res. 2002;59:41-69. doi: 10.1007/978-3-0348-8171-5_2.
Renewed interest in the mechanism of action of ribavirin results from its synergistic enhancement of interferon therapy and the need to develop more efficacious agents to treat hepatitis C virus infection. Since the discovery of ribavirin over 30 years ago by scientists at ICN Pharmaceuticals, many mechanisms of action for ribavirin have been proposed. These include inhibition of host inosine monophosphate dehydrogenase by ribavirin monophosphate, inhibition of viral capping enzymes, inhibition of viral RNA synthesis by ribavirin triphosphate, lethal mutagenesis of viral RNA genomes resulting from promiscuous incorporation of ribavirin triphosphate by the viral RNA polymerase, and modulation of the host immune responses. In this article, we will briefly review the evidence for these mechanisms, emphasizing recent findings. In addition, we will discuss strategies for development of nucleoside analogs that may replace ribavirin in the future.
对利巴韦林作用机制重新产生兴趣源于其对干扰素治疗的协同增强作用,以及开发更有效药物治疗丙型肝炎病毒感染的需求。自30多年前ICN制药公司的科学家发现利巴韦林以来,已提出了许多利巴韦林的作用机制。这些机制包括一磷酸利巴韦林对宿主肌苷单磷酸脱氢酶的抑制、对病毒封端酶的抑制、三磷酸利巴韦林对病毒RNA合成的抑制、病毒RNA聚合酶对三磷酸利巴韦林的随意掺入导致病毒RNA基因组的致死性诱变,以及宿主免疫反应的调节。在本文中,我们将简要回顾这些机制的证据,重点是近期的发现。此外,我们还将讨论未来可能取代利巴韦林的核苷类似物的开发策略。